September 2026
The global checkpoint inhibitor biologics CDMO market is growing as demand rises for outsourced biologics development and scalable immuno-oncology manufacturing.
September 2026
The global immune checkpoint inhibitors market size is predicted to hit around USD 258.91 billion by 2035 from USD 68.13 billion in 2025 with a CAGR of 16.03%.
September 2026
The global biologics CDMO market size was valued at USD 25.08 billion in 2026 and is projected to hit around USD 55.11 billion by 2035 with a healthy CAGR of 9.14%.
July 2026
The checkpoint inhibitor drugs market established a strong position in 2026 and is projected to expand significantly from 2026 through 2035, driven by increasing demand, evolving market needs, technological advancements, and growing adoption across key industries..
September 2026
The global aldose reductase inhibitor market size was evaluated at USD 7.24 billion in 2026 and is predicted to hit around USD 12.55 billion by 2035, growing at a CAGR of 6.30%.
September 2026
The global cell cycle inhibitors market size was evaluated at USD 6.13 billion in 2026 and is predicted to hit around USD 11.50 billion by 2035, growing at a CAGR of 7.23%.
September 2026
The global bone resorption inhibitors market size was evaluated at USD 4.13 billion in 2026 and is predicted to hit around USD 7.48 billion by 2035, growing at a CAGR of 6.82%.
September 2026
The global PD-1 inhibitor drugs market size was estimated at USD 56.29 billion in 2026 and is expected to hit around USD 201.87 billion by 2035, growing at a CAGR of 15.28% from 2026 to 2035.
September 2026
The anti-Inflammatory biologics market size reached USD 104.81 billion in 2024 and is projected to surpass around USD 185.51 billion by 2034 with a notable CAGR of 5.88%.
September 2026
The SGLT-2 inhibitors market size was USD 19.31 billion in 2026, with leading SGLT-2 inhibitors market players including Boehringer Ingelheim, Eli Lilly and Company.
September 2026
The global calcineurin inhibitors market size was evaluated at USD 11.17 billion in 2026 and is predicted to hit around USD 20.88 billion by 2035, growing at a CAGR of 7.20%.
September 2026
The global exosome-based cancer therapy CDMO market is growing as demand rises for scalable manufacturing and delivery solutions in exosome therapeutics.
September 2026
The global bispecific antibodies CDMO market expands with demand for next-generation therapeutics, advanced expression systems, and regulatory compliance expertise.
September 2026
The global oral solid dose oncology CDMO market is growing with rising demand for outsourced cancer drug manufacturing and advanced solid dosage formulation.
September 2026
The active pharmaceutical ingredients CDMO market reached USD 125.99 billion in 2026, with key active pharmaceutical ingredients CDMO market companies including Lonza, Thermo Fisher Scientific.
September 2026
The U.S. pharmaceutical CDMO market size was calculated at USD 46.55 billion in 2026 and is predicted to reach around USD 83.25 billion by 2034, with a CAGR of 7.47%.
September 2026
The global clean label mold inhibitors market size reached USD 1.31 billion in 2026 and is projected to be worth around USD 2.24 billion by 2034, with a notable CAGR of 6.93%.
September 2026
The global biologics market was valued at USD 534.30 billion in 2026 and is expected to hit around USD 1,243.80 billion by 2035, growing at a CAGR of 9.83%.
September 2026
The global veterinary CRO and CDMO market size was valued at USD 8.38 billion in 2026 and is predicted to surpass around USD 17.15 billion by 2035 with a CAGR of 8.30%.
September 2026
The global paraffin inhibitors market size was valued at USD 773.59 million in 2026 and is projected to hit around USD 1,180.61 million by 2035, at a CAGR of 4.81%.
September 2026
The global live biotherapeutic products and microbiome CDMO market size is estimated to hit around USD 1,838.56 million by 2035 from USD 106.79 million in 2026, at a CAGR of 37.38%.
September 2026
The LNP CDMO market reached USD 271.03 million in 2026, featuring leading LNP CDMO market companies such as Lonza Group, WuXi AppTec, Samsung Biologics.
September 2026
The rare disease small-batch CDMO market is expanding with demand for specialized manufacturing of orphan drugs and niche therapies.
September 2026
Europe Pharmaceutical CDMO market size is projected to hit around USD 94.94 billion by 2035, rising from USD 49.06 billion in 2026, growing at a CAGR of 7.59%.
September 2026
The interleukin inhibitors market size was exhibited at USD 34.30 billion in 2026 and is expected to surpass around USD 93.68 billion by 2035 with a CAGR of 11.83%.
September 2026
The global enzyme inhibitor market size is estimated to hit around USD 45.72 billion by 2034 increasing from USD 30.02 billion in 2026, with a CAGR of 5.40%.
September 2026
The global biologics and biosimilars market size is estimated to hit around USD 2,426.85 billion by 2035 increasing from USD 700.76 billion in 2026, with a CAGR of 14.80%.
September 2026
The global corrosion inhibitors market size was estimated at USD 9.58Â billion in 2026 and is projected to surge around USD 13.34 billion by 2034, with a CAGR of 4.22%.
September 2026
The global lipase inhibitors obesity drugs market size was estimated at USD 1.65 billion in 2026 and is expected to hit around USD 4.94 billion by 2034, growing at a CAGR of 14.72%.
September 2026
The global next-generation biologics market size was evaluated at USD 135.12 billion in 2026 and is predicted to hit around USD 301.22 billion by 2034, growing at a CAGR of 10.54% from 2025 to 2034.
+1 650 460 3308
+61 485 981 310 +91 87933 22019
sales@precedenceresearch.com